We use cookies to help provide you with the best possible online experience. Learn more

Press releases

Resolutions at the Annual General Meeting 2014

At the Annual General Meeting of RaySearch Laboratories AB (publ) held on 27 May, 2014, the following resolutions were adopted:

It was resolved that no dividends be paid out to the shareholders since the company is in a phase of rapid expansion that requires capital. The accumulated profit of SEK 29,461,000 was brought forward and balanced in the new accounts.

It was resolved to approve discharge from personal liability for the members of the Board and the President.

It was resolved to adopt the guidelines for remuneration to senior executives proposed by the Board, to apply until the close of the Annual General Meeting 2015.

It was resolved that remuneration to Board members who do not receive a salary from any Group company, total SEK 760,000 for the period extending to the close of the next Annual General Meeting, of which SEK 440,000 will be paid to the Chairman and SEK 160,000 to each of the Board members elected by the Annual General Meeting, who does not receive a salary from any Group company.

It was resolved that the Auditors’ fees be paid in accordance with current approved invoicing.

It was resolved to re-elect Carl Filip Bergendal, Erik Hedlund, Johan Löf and Hans Wigzell as Board members of the company and to re-elect Erik Hedlund as Chairman of the Board

It was resolved to re-elect the auditing firm Ernst & Young as auditors, with authorized public accountant Per Hedström as auditor in charge.

It was resolved to authorize the Board to resolve on new issues of Series B shares, on one or several occasions up until the Annual General Meeting of 2015, in accordance with the proposal by the Board.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch provides the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading partners such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-545 061 30